Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus? [2]

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 5, 2006, Pages 1910-

  Kalil, Andre C ^a   Puumala, Susan ^a   Stoner, Julie ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; DIARRHEA; DRUG MONITORING; DRUG SAFETY; HUMAN; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; SKIN INFECTION; SOFT TISSUE INFECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, MICROBIAL; HUMANS; METHICILLIN RESISTANCE; OXAZOLIDINONES; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 33646453323     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.5.1910-1911.2006     Document Type: Letter

References (2)

1. Moher, D., K. F. Schulz, and D. G. Altman. 2001. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. CONSORT GROUP (Consolidated Standards of Reporting Trials). Ann. Intern. Med. 134:657-662.
2. Weigelt, J., K. Itani, D. Stevens, W. Lau, M. Dryden, C. Knirsch, and the Linezolid CSSTI Study Group. 2005. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49:2260-2266.